Information Provided By:
Fly News Breaks for May 1, 2019
WST
May 1, 2019 | 08:45 EDT
Jefferies analyst David Windley downgraded West Pharmaceutical to Hold from Buy with an unchanged price target of $122 following the company's Q1 results. Slower growth on "significantly" tougher comps in Q2 and Q3 will bring the stock into a better entry point, Windley tells investors in a research note. The analyst views West Pharmaceutical's risk/reward as balanced at current "peak" valuation levels.
News For WST From the Last 2 Days
WST
WST
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.